SciELO - Scientific Electronic Library Online

 
vol.64 issue2Accreditation of services and quality of care for newborns in mexican hospitalsRisks of unintentional injuries at home: associated factors and their relation on the occurrence of injuries in vulnerable populations author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Salud Pública de México

Print version ISSN 0036-3634

Abstract

FIGUEROA-GARCIA, Juan et al. Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units. Salud pública Méx [online]. 2022, vol.64, n.2, pp.188-195.  Epub Mar 13, 2023. ISSN 0036-3634.  https://doi.org/10.21149/12972.

Objective:

To estimate the increase of drug treatment costs associated with predictive factors of hypertensive patients in family medicine units.

Materials and methods:

A generalized linear model was employed to estimate costs with data from a microcosting costing study for a 1-year time horizon. Sources of dada were medical electronic files, pharmacy records and unitary prices updated to 2019.

Results:

From a total of 864 patients older than 65 years were 67% and women 65%. Factors with most influence on mean drug treatment costs were diabetes, age and complications associated with hypertension. Mean annual cost of antihypertensive treatment was 61 dollars (CI95% 55,67) and median were 32 dollars (IQR 30,35) per patient. Incremental costs for diabetes were 23 dollars (CI95% 13,33) and 25 dollars (CI95% 5, 45) in the group of ≥ 65 years.

Conclusion:

Diabetes, age and complications were the factors with largest influence on hypertension pharmacological costs.

Keywords : Hypertension; cost allocation; drug therapy.

        · abstract in Spanish     · text in English     · English ( pdf )